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Summary
Statins are the cornerstone of the management of dyslipid-
aemias and prevention of cardiovascular disease. Although
statins are, overall, safe and well tolerated, adverse events
can occur and constitute an important barrier to maintain-
ing long-term adherence to statin treatment. In patients
who cannot tolerate statins, alternative treatments include
switch to another statin, intermittent-dosage regimens and
non-statin lipid-lowering medications. Nonetheless, a high
proportion of statin-intolerant patients are unable to
achieve recommended low-density lipoprotein (LDL) cho-
lesterol goals, thereby resulting in substantial residual car-
diovascular risk. Proprotein convertase subtilisin/kexin
type 9 (PCSK9) is a protease implicated in LDL receptor
degradation and plays a central role in cholesterol meta-
bolism. In recent studies, PCSK9 inhibition by means of
monoclonal antibodies achieved LDL cholesterol reduc-
tions of 50% to 70% across various patient populations
and background lipid-lowering therapies, while maintain-
ing a favourable safety profile. The efficacy and safety
of the monoclonal antibodies alirocumab and evolocumab
were confirmed in statin-intolerant patients, indicating that
PCSK9 inhibitors represent an attractive treatment option
in this challenging clinical setting. PCSK9 inhibitors re-
cently received regulatory approval for clinical use and
may be considered in properly selected patients according
to current consensus documents, including patients with
statin intolerance. In this review we summarise current
evidence regarding diagnostic evaluation of statin-related
adverse events, particularly statin-associated muscle symp-
toms, and we discuss current recommendations on the man-
agement of statin-intolerant patients. In view of emerging
evidence of the efficacy and safety of PCSK9 inhibitors,
we further discuss the role of monoclonal PCSK9 antibod-
ies in the management of statin-intolerant hypercholestero-
laemic patients.
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Introduction
The efficacy of statins for reduction of low-density lipo-
protein cholesterol (LDL-C) and prevention of cardiovas-
cular events is well established [1, 2]. Statins are the most
widely prescribed class of drugs worldwide and are gener-
ally safe and well tolerated; however, statin intolerance is
not uncommon in real-world practice [3]. Skeletal muscle-
related events are the most frequent adverse event associ-
ated with statin treatment, followed by asymptomatic liv-
er enzyme elevation and other, less frequent, side effects
[4]. While adverse events are in principle fully reversible
upon statin withdrawal or dose reduction, they constitute
an important barrier to maintaining long-term compliance
with statin treatment [5]. Furthermore, a substantial propor-
tion of patients – both statin-tolerant and, to a greater ex-
tent, statin-intolerant – are unable to achieve recommen-
ded LDL-C goals despite alternative treatment strategies
including switch to another statin, intermittent-dosage stat-
in regimens, and/or non-statin lipid-lowering medications.
Thereby, residual cardiovascular risk is particularly preval-
ent among high-risk, secondary prevention patients.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a
secreted protein that enhances degradation of the LDL re-
ceptor and thereby plays a central role in LDL-C metabol-
ism [6]. Consequently, inhibition of PCSK9 has emerged
as a promising new target in lowering plasma LDL-C. In
recent studies, monoclonal antibodies that functionally in-
hibit PCSK9 achieved LDL-C reductions of 50% to 70%
across various patient populations and background lipid-
lowering therapies while maintaining a favourable safety
profile [7, 8]. PCSK9 inhibitors have specifically been
tested in statin-intolerant patients and resulted in greater re-
ductions of LDL-C levels and fewer adverse effects com-
pared with other non-statin medications [9, 10], thus rep-
resenting an attractive treatment option in this clinical set-
ting.
In this review we summarise evidence regarding the in-
cidence, risk factors and diagnostic evaluation of statin-
related adverse events, particularly statin-associated my-
opathy, and we discuss current recommendations on the
management of statin-intolerant patients. In view of emer-
ging evidence of the efficacy and safety of PCSK9 inhib-
itors, we further discuss the role of monoclonal PCSK9
antibodies for management of statin-intolerant hypercho-
lesterolaemic patients.
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Statin intolerance: incidence and
clinical impact
Statins represent the cornerstone of the management of
dyslipidaemias and prevention of cardiovascular disease
[1, 2]. The Cholesterol Treatment Trialists’ (CTT) collab-
oration, an individual-patient pooled dataset including
>170 000 patients, demonstrated a reduction in the annual
rate of major vascular events by 22% with each LDL-C
reduction og 1 mmol/l and thereby provided unequivocal
evidence of substantial cardiovascular benefit across the
spectrum of patient risk categories [11, 12]. Although stat-
ins are generally safe and well tolerated, a number of ad-
verse effects have been attributed to them. These include
muscle-related symptoms, liver enzyme elevation and a
slightly elevated risk of new-onset diabetes [13], as well
as other potential side effects with less-established eviden-
ce of causality such as gastrointestinal discomfort, insom-
nia and neurocognitive symptoms [14]. The absolute ex-
cess risk of these adverse effects of statins is very small and
is outweighed by well-established beneficial effects on ma-
jor cardiovascular events.
Statin-associated muscle symptoms represent the leading
manifestation of statin intolerance. Skeletal muscle-related
adverse events range from symptoms with normal creatine
kinase (CK) levels (“myalgia”) to a combination of symp-
toms with minor to moderate CK elevation [<10× the upper
limit of the normal range (ULN)] or more marked CK el-
evation >10× ULN (“myositis”), to extremely rare cases of
rhabdomyolysis (CK elevation >40× ULN associated with
renal impairment and/or myoglobinuria) [5]. Accurate es-
timation of the incidence of statin-associated muscle symp-
toms is hindered by the vast heterogeneity of definitions
across clinical studies and regulatory reports. Randomised
trials found similarly low rates of myalgia in patients
treated with statin or placebo [15, 16]. In contrast, observa-
tional studies reported statin-associated muscle symptoms
in 7–11% [17, 18] up to 29% in a single study [19], most
commonly associated with normal or slightly elevated CK
concentrations. More marked CK elevations (>10× ULN)
were observed in 1 per 1000 to 1 per 10 000 patients per
year [20], depending on the statin type and dosage, and
presence of risk factors. In this context, it is important to
consider that the exclusion of patients who are at highest
risk of developing side effects from most randomised trials
likely resulted in an underestimation of the true rate of ad-
verse events. On the other hand, muscle symptoms are a
nonspecific complaint (table 1), such that frequently repor-
ted muscle symptoms in statin-treated patients may not be
attributable to statins in observational registries [20].
Statin-associated myopathy is largely clinically benign, in
that symptoms as well as CK elevations are reversible upon
withdrawal of the statin in the vast majority of affected
patients. Persistent muscle symptoms during statin treat-
ment are accompanied by characteristic histological pat-
terns of muscle damage [21], and there is some evidence
that statins may induce long-standing ultrastructural mus-
cular changes, even in the absence of symptoms [22]. In
extremely rare cases, an autoimmune myopathy develops
in patients treated with statins; this disorder results in pro-
gressive weakness that must be controlled with immun-
osuppressive therapy [23]. While in principle benign and
reversible, statin-induced muscle symptoms may com-
promise physical activity – an important component of car-
diovascular prevention. Importantly, these side effects have
substantial impact on drug adherence and consequently on
cardiovascular risk reduction, as they frequently result in
discontinuation or suboptimal dosing of statins [5]. Dis-
continuation rates amount to 75% in patients who develop
muscle-related symptoms [24]; the occurrence of side ef-
fects is in fact the main reason for nonadherence to statin
therapy [25]. Notably, low adherence to statin therapy is as-
sociated with a 25% increase in all-cause mortality [26] and
a 15% increase in cardiovascular risk [27] among second-
ary prevention patients.
Risk factors that increase the likelihood of statin-induced
myopathy include demographic features (advanced age,
frailty, Asian descent); genetic factors; and patient co-mor-
bidities [3, 5] (table 2). Moreover, differences in physico-
chemical properties of each statin, and their metabolism
and dosage influence the risk of developing myopathy. For
any given statin, the risk of developing muscle symptoms
is higher with increasing doses. Similarly, growing num-
bers of patients are expected to receive treatment with high-
dose statins in the future as the importance of adequately
controlled blood lipid levels for prevention of cardiovascu-
lar disease is increasingly appreciated [28, 29], and as ge-
netic (familial) forms of hypercholesterolaemia are increas-
ingly recognised [30]. All statins can cause muscle symp-
toms, but the risk appears to vary between different statins
and appears to be lowest with fluvastatin and pravastatin
[31]. In-vitro studies suggested greater direct muscle tox-
icity with lipophilic statins (simvastatin, lovastatin), where-
as more hydrophilic statins (pravastatin, rosuvastatin) may
be less toxic due to lower penetration into muscle cells
[32]; however, individual patient differences are likely
more important than statin differences in affecting statin
uptake by skeletal muscle tissue. Pharmacokinetic inter-
actions with concomitant medications represent a well-es-
tablished risk factor of statin-induced myopathy. The pos-
sibility of drug interactions is higher for statins mainly
metabolised by the CYP3A4 enzyme system (simvastatin,
atorvastatin, lovastatin) than with rosuvastatin and pravast-
atin, which are not extensively metabolized by CYP3A4.
Medications with the potential for drug-drug interactions
that increase statin exposure and thereby raise the risk of
myopathy include potent CYP3A4 inhibitors (itraconazole,
ketoconazole, macrolides), human immunodeficiency virus
(HIV) protease inhibitors, immunosuppressive drugs
(ciclosporin), and commonly prescribed cardiovascular
medications (amiodarone, diltiazem, verapamil).
Regarding hepatic involvement, asymptomatic liver en-
zyme elevation is observed in 0.1–3.0% of treated patients
and is a dose-dependent class effect for statins [33]. The
condition is considered clinically benign and is not accom-
panied by histological alterations in the liver. Clinically rel-
evant hepatic impairment is very infrequent and requires
exclusion of secondary causes or possible drug-drug inter-
actions. Of note, elevated enzyme levels tend to normalise
despite continuation of therapy, which is likely related to
statin-mediated reduction in hepatic steatosis [34]. It is, in
fact, believed that liver enzyme elevation may represent ad-
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aptation of the liver to lower LDL-C levels rather than true
hepatic toxicity [35].
Diagnostic assessment of statin-
associated muscle symptoms
Definitive diagnosis of statin-associated myopathy is diffi-
cult because of the subjective, nonspecific symptoms and
the absence of a gold-standard diagnostic test. A combin-
ation of clinical and laboratory findings can help to assess
the probability that muscle complaints are indeed caused
by a statin. The localisation of symptoms, magnitude of
CK elevation and temporal association with statin initi-
ation, discontinuation or re-challenge need to be carefully
reviewed. Statin-induced muscular complaints are typic-
ally symmetrical and proximal, and generally affect large
muscle groups including the thighs, buttocks, calves and
back muscles [5]. These symptoms usually occur early
(within 4–6 weeks) after starting statin therapy or increas-
ing the dose [36], although delayed occurrence (even after
years of treatment) is possible. Symptoms may be triggered
by an increase in statin dose, initiation of interacting med-
Table 1: Differential diagnosis of muscle symptoms or creatine
kinase elevation.
Hypo-/hyperthyroidism
Excessive physical activity
Trauma
Viral infection
Vitamin-D deficiency
Rheumatic disorders (polymyositis, systemic lupus erythematosus)
Peripheral arterial disease
Medications (glucocorticoids, antipsychotics, immunosuppressant,
gemfibrozil)
Substance abuse (opioids, cocaine, amphetamines)
Metabolic/infectious myopathies
Neuropathies
Table 2: Risk factors and precipitating factors of statin-associated
myopathy. Adapted with permission from [5].
Demographic factors
Age >80 years
Female gender
Low body mass index
Asian descent
Comorbidities
Acute infection
Hypothyroidism (untreated or undertreated)
Impaired renal/hepatic function
Biliary tree obstruction
Organ transplant recipients
Severe trauma
Human immunodeficiency virus infection
Diabetes mellitus
Vitamin D deficiency
Surgery with high metabolic demands
Relevant history
History of creatine kinase elevation
History of pre-existing muscle/joint/tendon pain
Inflammatory or metabolic neuromuscular defects
Previous statin-induced myopathy
Previous myotoxicity by non-stain lipid-lowering medications
Other risk factors
Genetic factors (polymorphisms in genes encoding CYP450
isoenzymes)
Dietary effects (grapefruit juice)
Excess alcohol use
Drug abuse (cocaine, amphetamines, heroin)
ications, or presence of precipitating factors (e.g., alcohol
excess, drug abuse, major surgery) (table 2), and are more
frequent in physically active individuals. Recently, a risk
score was proposed, incorporating the aforementioned clin-
ical and laboratory variables, to facilitate differential dia-
gnosis and define the probability that muscle complaints
and/or CK elevation are attributed to statins [37].
Management of statin-intolerant
patients
Initial evaluation of stain-treated patients who present with
muscle symptoms should focus on exclusion of alternative
causes and identification of possible precipitating factors.
Along these lines, glucocorticoids, antipsychotic
(risperidone, haloperidol), immunosuppressant or antiviral
agents (HIV protease inhibitors) and lipid-modifying drugs
(gemfibrozil), as well as alcohol or drug abuse (opioids,
cocaine) are potential causes of muscle-related symptoms
irrespective of statin use. Once secondary causes or trig-
gering factors are excluded, the need for continued statin
therapy should be re-evaluated on the basis of individual
patient risk. For patients at high or very high cardiovascular
risk (e.g., those with known cardiovascular disease, famili-
al hypercholesterolaemia or diabetes mellitus), the benefits
of statin therapy need to be weighed against the burden of
muscle symptoms. As general measures, patients need to
be counselled regarding the risk of side effects and the high
probability that these can be dealt with successfully, and
the role of dietary or other lifestyle measures for cardiovas-
cular risk reduction needs to be emphasised [5].
A treatment algorithm for patients with statin-associated
muscle symptoms was proposed in a recent consensus
statement by the European Atherosclerosis Society [5]
(fig. 1). Withdrawal of statin therapy usually leads to res-
olution of symptoms and, along with symptom recurrence
upon re-challenge, can help determine a causal link
between the drug and the adverse event. In patients with
initial CK elevation <4× ULN, statin cessation with a 2–4
week washout period is recommended; persistence of
symptoms practically excludes the causal role of the statin
regimen. If symptoms improve, treatment with a lower
dose of the same statin or with an alternative statin should
be considered. Doses can be up-titrated to achieve LDL-C
goals or reduce LDL-C to the maximal extent with minim-
al muscle complaints. More efficacious statins with a long
half-life (rosuvastatin, atorvastatin, pitavastatin), usually
starting at a lower dose, or intermittent (non-daily) regi-
mens are recommended. In the case of higher initial CK el-
evation (>4× ULN), a low-dose or alternate day regimen of
a potent statin is recommended after a prolonged (6-week)
washout resulting in symptom improvement and normaliz-
ation of CK levels (fig. 1). In the extremely rare event of
rhabdomyolysis, statins should not be reintroduced.
In the proposed algorithm, the primary goal is achievement
of LDL-C targets with maximally tolerated statin doses.
However, combination with non-statin therapies is recom-
mended in patients at high risk for cardiovascular disease
with LDL-C levels above respective targets despite maxim-
ally tolerated statin therapy. Ezetimibe reduces LDL-C by
15–20%, has few side effects [38] and has been shown to
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reduce cardiovascular events when added to statin therapy
[39]. Other non-statin lipid-lowering medications include
bile acid sequestrants and fenofibrate (which, unlike gem-
fibrozil, does not increase the risk of rhabdomyolysis when
added to a statin). Niacin is no longer prescribed in Europe
because of reports of excessive adverse effects without car-
diovascular benefit [40]. Although complementary therapy
with ubiquinone (coenzyme Q10) has been suggested to
improve statin tolerability, this approach has not proven ef-
fective in randomised controlled trials [41] and is currently
not recommended [5]. It is important to note that statins
are believed to confer cardiovascular benefits by means of
pleotropic effects beyond their LDL-C–lowering potential
(e.g., favourable effects on atherosclerotic plaque composi-
tion [42, 42], anti-inflammatory effects [44], immunomod-
ulatory properties [45], or direct effects of the vascular
endothelium). Whether these properties are also afforded
by non-statin lipid-lowering medications is unclear and re-
mains to be determined. Along these lines, recent eviden-
ce demonstrated the incremental value of ezetimibe when
added to a statin for regression of coronary atherosclero-
sis [46] and reduction of blood levels of C-reactive protein
[47].
Regarding liver enzyme elevation, the Swiss Atheroscler-
osis Association recommends continued statin treatment
in the event of aspartate transaminase and alanine transa-
minase levels <3× ULN and repeated checking after 4–6
weeks. If enzyme levels are >3× ULN, statin discontinu-
ation or dose reduction is recommended, followed by a re-
peat check after 4–6 weeks and treatment resumption once
enzymes return to normal.
Figure 1
Proposed algorithm for management of patients with statin-
associated muscle symptoms. Adapted with permission from [5].
CETP = cholesteryl ester transfer protein; CK = creatine kinase;
LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein
convertase subtilisin/kexin type 9; ULN = upper limit of the normal
range
a efficacious stain such as atorvastatin or rosuvastatin
* Reiner et al. 2011 [28]
PCSK9 inhibitors: overview of efficacy
and safety
PCSK9 is a serine protease that promotes degradation of
the LDL receptor, thereby resulting in reduced hepatic up-
take and increased circulating levels of LDL-C [6]. In
2003, mutations in the PCSK9 gene were identified as one
of the causes of familial hypercholesterolaemia [48]. Gain-
of-function mutations in PCSK9 are associated with elev-
ated LDL-C levels and premature cardiovascular disease,
whereas loss-of-function mutations in PCSK9 result in re-
duced LDL-C levels and lower cardiovascular event rates
[49]. Following these observations, intensive research has
focused on the development of therapeutic approaches to
inhibition of PCSK9 function as a means of lowering ath-
erogenic lipoprotein levels; these approaches include an-
tibodies, antisense oligonucleotides and small interfering
RNAs targeting PCSK9 synthesis. Currently, monoclonal
antibodies are the most advanced and clinically documen-
ted approach to PCSK9 inhibition. In several published
phase II and phase III studies, PCSK9 inhibitors were able
to decrease LDL-C by 50–70% across a wide range of pa-
tient populations and background therapies, including pa-
tients who were unable to tolerate statin therapy, patients
with heterozygous and homozygous familial hypercholes-
terolaemia, or patients unable to reach LDL-C targets des-
pite lipid-lowering medications [7, 8]. In these studies,
LDL-C reductions were consistent and dose-dependent,
and were not affected by age, gender, or baseline LDL-C
concentrations.
Current evidence on PCSK9 inhibitors is reviewed in detail
elsewhere [50]. Here we briefly discuss the largest pub-
lished phase III studies of the two most extensively studied
antibodies, alirocumab (Regeneron/Sanofi) and evolocu-
mab (Amgen). The randomised, placebo-controlled
ODYSSEY LONG-TERM trial evaluated the efficacy and
safety of treatment with alirocumab for 78 weeks in 2341
patients with established coronary heart disease (CHD) or
CHD equivalent with LDL-C levels ≥70 mg/dl (≥1.8
mmol/l) on maximum tolerated statin dose or other lipid-
lowering therapy [51]. Alirocumab resulted in a reduction
of LDL-C levels by 61% at 24 weeks and by 52% at 78
weeks. Reductions in non-HDL cholesterol of 52%, apol-
ipoprotein B of 54%, and lipoprotein(a) of 26% were also
observed. The goal of an LDL-C level <1.8 mmol/l was
met by 79% of patients in the alirocumab group compared
with 8% of patients in the placebo group. In a predefined
exploratory analysis, treatment with alirocumab was asso-
ciated with a 48% lower rate of major adverse cardiovascu-
lar events compared with placebo (hazard ratio [HR] 0.52;
95% confidence interval [CI] 0.31–0.90; p = 0.02) [51].
Evolocumab was studied in two open-label, randomised tri-
als (OSLER 1 and OSLER 2) [52]. A total of 4465 patients
were randomised in a 2:1 ratio to receive either evolocu-
mab (140 mg every 2 weeks or 420 mg monthly) plus
standard therapy or standard therapy alone. After 12 weeks
of treatment, evolocumab reduced LDL-C by 61% to a
median level of 48 mg/dl; this reduction was maintained
throughout 48 weeks of follow-up. In a post-hoc analys-
is, treatment with evolocumab was associated with a signi-
ficantly lower rate of cardiovascular events at 1 year com-
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pared with standard therapy (HR 0.47; 95% CI 0.28–0.78;
p = 0.003) [52]. In a pooled meta-analysis including 17 tri-
als with 13 083 patients randomised to PCSK9 inhibitors
(alirocumab or evolocumab), ezetimibe or placebo, PCSK9
inhibitors reduced LDL-C by 57% relative to placebo and
36% relative to ezetimibe, and were associated with a 57%
reduction in all-cause mortality (odds ratio 0.43, 95% CI
0.22–0.82; p = 0.01) [53].
Adding to the marked efficacy in reducing levels of LDL-
C and other atherogenic lipoproteins, the safety and toler-
ability of the two most extensively studied antibodies ap-
pears to be promising in up to 2 years of follow-up. In
the OSLER trials, adverse events occurred with similar fre-
quency in the two groups, with the exception of neurocog-
nitive events which were more frequent in the evolocumab
group, and did not vary according to the achieved level
of LDL-C [52]. Similarly, alirocumab was tolerated well
without a significant increase in adverse effects attribut-
able to the study drug in the ODYSSEY LONG TERM trial
[51]. The finding of a two-fold higher incidence of neuro-
cognitive adverse events with PCSK9 inhibitors than with
placebo in a pooled meta-analysis [53] requires further in-
vestigation in larger patient cohorts with longer follow-
up, and is currently being tested in a dedicated study of
evolocumab (the EBBINGHAUS study; ClinicalTrials.gov
Identifier: NCT02207634).
Studies investigating PCSK9 inhibitors
in statin-intolerant patients
In published studies testing PCSK9 inhibitors, large LDL-
C reductions were associated with very low rates of muscle
symptoms, thus reinforcing the concept that statins and
not LDL-C lowering per se are implicated in the devel-
opment of muscle-related symptoms. Both alirocumab and
evolocumab have been assessed specifically in formally
statin-intolerant patients.
The GAUSS-2 randomised trial compared the efficacy and
safety of evolocumab versus ezetimibe in 307 hypercholes-
terolaemic patients unable to tolerate effective statin doses
[9]. Patients had baseline LDL-C levels above their NCEP
ATP-III risk category goal, i.e., ≥100 mg/dl (2.6 mmol/
l) with diagnosed CHD or risk equivalent; ≥130 mg/dl
(3.4 mmol/l) with two or more risk factors; ≥160 mg/dl
Figure 2
Kaplan-Meier estimates for time to first skeletal muscle-related
adverse event across treatment groups in the ODYSSEY
ALTERNATIVE randomised trial. Adapted with permission from
[10].
ALI = alirocumab; ATV =atorvastatin; CI = confidence interval; EZE
= ezetimibe; HR = hazard ratio.
(4.1 mmol/l) with a single risk factor; or ≥190 mg/dL (4.9
mmol/l) without CHD and without risk factors. Evidence
of intolerance to at least two statins was an inclusion cri-
terion. Patients were randomised to evolocumab 140 mg
every 2 weeks or 420 mg monthly plus oral placebo, or to
subcutaneous placebo plus ezetimibe. Mean percent LDL-
C reductions from baseline to 12 weeks were 56% with
evolocumab 140 mg every 2 weeks and 55% with 420
mg once monthly, corresponding to treatment differences
of 37% and 39%, respectively, compared with ezetimibe.
Attainment of LDL-C targets within 12 weeks was more
frequent in patients treated with evolocumab than with
ezetimibe (76% vs 5.5%). Muscle-related adverse events
occurred in 12% of evolocumab-treated patients and 23%
of ezetimibe-treated patients, and rates of discontinuation
due to musculoskeletal side effects were 5% in the evolocu-
mab compared with 6% in the ezetimibe group [9].
In the ODYSSEY ALTERNATIVE trial, alirocumab was
evaluated in 314 patients with statin intolerance [10]. Un-
like GAUSS-2, this trial had a more extended follow-up
of 24 weeks and included a statin rechallenge arm in an
attempt to confirm intolerance. Patients were randomised
to alirocumab 75 mg every 2 weeks, ezetimibe 10 mg
daily, or atorvastatin 20 mg daily. At 24 weeks, reduction
in LDL-C was 45% with alirocumab as compared with
15% in ezetimibe-treated patients. Treatment-related ad-
verse events did not differ between groups. Rates of skelet-
al muscle-related events were lower in the alirocumab than
in the atorvastatin group (HR 0.61, 95% CI 0.38–0.99; p
= 0.04), with a similar trend for the comparison between
alirocumab and ezetimibe (HR 0.71, 95% CI 0.47–1.06; p
= 0.096) [10] (fig. 2).
PCSK9 inhibitors in statin-intolerant
patients: current status and future
perspectives
Statin-associated adverse events, particularly myopathy, af-
fect a non-negligible proportion of treated patients, and
the global burden of statin intolerance is magnified by
the large numbers of patients receiving statins worldwide.
While proposed management strategies including alternat-
ive statin– and non-statin–based regimens are effective at
least in part, there remains an unmet need for improved
lipid lowering, particularly among true statin-intolerant pa-
tients who are at high cardiovascular risk and cannot reach
established LDL-C targets. According to current evidence
in populations selected on the basis of documented statin-
induced myopathy [9, 10], LDL-C reduction was more
pronounced and muscle adverse events were less frequent
following treatment with PCSK9 inhibitors than with eze-
timibe, the most widely used non-statin drug in this clinical
setting. These studies provided evidence of marked effic-
acy combined with favourable tolerability, thereby placing
PCSK9 monoclonal antibodies as a promising therapy for
treatment of high-risk statin-intolerant patients with per-
sistently elevated blood lipid levels.
Alirocumab and evolocumab were recently approved for
clinical use by the US Food and Drug Administration as
well as the European Medicines Agency (EMA). Accord-
ing to the EMA approval [54, 55], these antibodies are
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indicated in adults with primary hypercholesterolaemia or
mixed dyslipidaemia, as an adjunct to diet: (i) in combin-
ation with a statin, or statin with other lipid-lowering ther-
apies in patients unable to reach LDL-C goals with the
maximum tolerated dose of a statin; or (ii) alone or in
combination with other lipid-lowering therapies in patients
who are statin-intolerant. In Switzerland, evolocumab was
approved by the Swiss Agency for Therapeutic Products,
Swissmedic, in February 2016 [56].
In addition to regulatory approval, current scientific docu-
ments indicate that PCSK9 monoclonal antibodies may be
considered for properly selected patients, including those
with statin intolerance. In a consensus statement on statin-
associated muscle symptoms by the European Atheroscler-
osis Society [5], PCSK9 inhibitors were included in the rel-
evant treatment algorithm (fig. 1) and were reserved for
patients with LDL-C above target levels despite maxim-
ally tolerated statin doses and addition of non-statin med-
ications (ezetimibe, fibrates or bile acid absorption inhib-
itors). The aforementioned approach is relatively conser-
vative with regard to the use of PCSK9 inhibitors, but
needs to be interpreted in view of the fact that the con-
sensus paper [5] was published prior to publication of the
two largest studies to date attesting to the efficacy and
safety of PCSK9 monoclonal antibodies [51, 52]. Subse-
quently, recommendations were issued by the US Nation-
al Lipid Association, indicating that PCSK9 inhibitors may
be considered in selected high- or very high-risk patients
who are statin-intolerant and require substantial additional
cholesterol reduction despite the use of other lipid lower-
ing therapies [57]. An updated guideline document by the
European Society of Cardiology on the management of
dyslipidaemias will be published in 2016 and is expected
also to provide recommendations with regard to the use of
PCSK9 inhibitors in statin-intolerant patients.
Collectively, patients who are at high cardiovascular risk
but cannot achieve LDL-C goals as a result of statin intol-
erance appear to be particularly well suited for treatment
with PCSK9 inhibitors. Currently, more evidence is expec-
ted from ongoing trials focusing on the long-term safety
and efficacy of alirocumab (the ODYSSEY Outcomes trial;
NCT01663402), evolocumab (the FOURIER trial;
NCT01764633) and the monoclonal antibody bococizumab
(Pfizer) (SPIRE 1 trial; NCT01975376 and SPIRE 2 trial;
NCT01975389). These studies will primarily test the im-
pact of PCSK9 monoclonal antibodies on long-term car-
diovascular outcomes and will thereby determine whether
the documented LDL-C reduction and promising effects on
mid-term clinical outcomes by means of pharmacologic-
al PCKS9 inhibition [53, 58] translate into definitive evid-
ence of long-term cardiovascular benefit. Of note, there
have been concerns that the high production cost and cur-
rently high market price may become appreciable barriers
to wide-spread use of these effective medications [59]. As
in the case of statins [60], robust evidence of clinical bene-
fit with these agents will be required for definitive afford-
ability assessment and cost-effectiveness analyses. Wheth-
er PCSK9 inhibitors prove broadly effective for cardiovas-
cular event reduction, and whether healthcare savings due
to the afforded clinical benefit might counterbalance treat-
ment cost remains to be determined. The expected new in-
sights from ongoing studies will significantly influence fu-
ture recommendations as well as real-world penetration of
these promising therapies overall – and specifically in the
challenging setting of statin-intolerant patients.
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Figures (large format)
Figure 1
Proposed algorithm for management of patients with statin-associated muscle symptoms. Adapted with permission from [5].
CETP = cholesteryl ester transfer protein; CK = creatine kinase; LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase
subtilisin/kexin type 9; ULN = upper limit of the normal range
a efficacious stain such as atorvastatin or rosuvastatin
* Reiner et al. 2011 [28]
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Figure 2
Kaplan-Meier estimates for time to first skeletal muscle-related adverse event across treatment groups in the ODYSSEY ALTERNATIVE
randomised trial. Adapted with permission from [10].
ALI = alirocumab; ATV =atorvastatin; CI = confidence interval; EZE = ezetimibe; HR = hazard ratio.
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